Inner Harbor-based biotech company PathSensors will be acquired by global security screening and threat detection company Smiths Detection, the companies announced this week.
With the deal, PathSensors will become part of a London-based company with 2,200 employees and a U.S. headquarters in Edgewood.
Image: PathSensors is headquartered at Columbus Center. (Photo by Wikimedia Commons user Smash the Iron Cage, used under Creative Commons license)
Gentian Diagnostics AS is pleased to announce that the Research Council of Norway (Norges Forskningsråd) has awarded Gentian up to NOK 8.0 million of funding to support the development of a high-throughput COVID-19 antibody test. Gentian has in cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway performed explorative test work that supports an idea of developing a COVID-19 antibody test based on Gentian’s proprietary technology. The assay, if successfully developed, will be designed for use on clinical analysers already available in major laboratories around the world.
Welcome to GEN’s COVID-19 DRUG & VACCINE CANDIDATE TRACKER website.
Total Drug & Vaccine Candidates: 237 (as of June 8)
The goal of this resource is to provide a comprehensive collection of news, milestones, and updates on drug and vaccine candidates currently being developed for the COVID-19 pandemic.
This resource is based on the reporting of GEN senior news editor Alex Philippidis, who began compiling information on drug and vaccine candidates in the early weeks of the pandemic. The numbers of verified candidates ballooned rapidly from 35 in February 2020, to 60 in March, to 160 in April.
September 12, 2020
Special Guests Including:
Dr. Michele McMurry-Hearth
President and CEO,
Biotechnology Innovation Organization (BIO)
GAITHERSBURG, Md., June 29, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD). The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial.
Emergent BioSolutions (NYSE:EBS) has closed a five-year agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals for large-scale drug substance manufacturing for J&J’s SARS-CoV-2 vaccine, Ad26.COV2-S.
EBS will provide contract development and manufacturing services over the contract term valued at ~$480M for the first two years. Volume manufacturing will start in 2021 at its Baltimore Bayview facility subsequent to technology transfer.
The company will release updated 2020 guidance when it reports Q2 results.
JNJ is up 2% premarket and EBS up 1%, both on light volume.
Across the country today, not just in Boston and San Francisco, in leading and emerging life science clusters, life sciences institutions and innovative companies are working on cell and gene therapies, corona virus vaccines and drugs, and new bioengineering technologies that have the potential to change the way we feed, fuel and heal the world.
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”), a privately held biotech company based in San Diego, CA, announced today that the companies have entered into a license agreement to support the development of ITI’s investigational plasmid DNA vaccine therapy, ITI-1001.
ITI will leverage Ichor’s TriGrid® Electroporation technology to increase cellular uptake of ITI-1001 when administered to patients with newly diagnosed Glioblastoma, or GBM. DNA vaccines delivered by conventional injection have experienced challenges to delivery efficiency, resulting in suboptimal immune responses in clinical trials. Ichor’s TriGrid technology utilizes the application of electrical fields in a target tissue to increase intracellular nucleic acid uptake in the local area, resulting in enhanced gene expression.
The latest issue of The Life Sciences Report features an interview with Matthew J. Meyer, the firm’s chief client corporate development officer, who has broad management experience in the life sciences sector; a piece authored by Paul Grand and Kathryn Zavala of MedTech Innovator outlining 10 reasons why health care start-ups fail; an interview with Ryan Phelan, co-founder and executive director of Revive & Restore, a 501(c)(3) foundation using 21st century biotechnology to address urgent conservation challenges; and an article by Paul P. Campbell of W. L. Gore & Associates on life sciences innovation culture and deconstruction. In addition, the publication includes articles covering life sciences venture financings in which firm clients participated during 2019, the FDA’s recent issuance of a MAPP on the conversion of ANDA approval to tentative approval, and a sampling of COVID-19-related client activity in which the firm has been involved, as well as a summary of other select recent life sciences client highlights.
Image: https://www.jdsupra.com